Orvepitant

About NeRRe Therapeutics

NeRRe Therapeutics was a clinical-stage biotech founded in 2012, originating from a GSK spin-out, with a specialized focus on neurokinin receptor antagonists. Its lead asset, orvepitant, reached Phase II development for chronic refractory cough and other conditions. The company ultimately ceased operations, indicating a failure to secure further funding or a strategic exit, with its intellectual property and assets presumably managed by appointed administrators.

About NeRRe Therapeutics

NeRRe Therapeutics was a clinical-stage biotech founded in 2012, originating from a GSK spin-out, with a specialized focus on neurokinin receptor antagonists. Its lead asset, orvepitant, reached Phase II development for chronic refractory cough and other conditions. The company ultimately ceased operations, indicating a failure to secure further funding or a strategic exit, with its intellectual property and assets presumably managed by appointed administrators.

Therapeutic Areas